Various vaccine platforms in the field of COVID-19

K. Savina, Rakhy Sreekumar, V. K. Soonu and E. J. Varyiar*

Abstract

Background: With the emergence of Corona virus Disease-2019, a novel worldwide health disaster is threatening the population. The WHO declared COVID-19 as a pandemic in December 2019, when it first surfaced in Hunan seafood market in Wuhan, South China, and quickly spread far and wide. Different corona virus variants are currently causing concern all across the world.

Main body: It has become critical for our scientists to develop a viable method to prevent infection or the pandemic from spreading globally. Antiviral medicines, oxygen therapy, and immune system stimulation are all used to treat the condition. SARS-CoV-2 undergoes mutation and due to evolutionary pressures, different mutant strains caused various symptoms in different geographical regions and the epidemic is spreading and becoming more fragile, posing a greater risk of mortality. Vaccines are tools to increase our immunity as a precaution, and increasing the global immunization rate can help improve the situation. Recent developments in the field of vaccine platforms are discussed here.

Short conclusion: Vaccines are of highest priority to control and eradicate the viral infectious disease COVID-19 more than any other protective solutions. A number of mutations have occurred and some variants such as alpha, beta, gamma, and delta, and it has now progressed to the new version Omicron, which is a variant of concern. Booster doses are anticipated to function as a barrier to the capacity of the most recent known variety, and more research is needed to determine how effective they will be. This page discusses various technologies employed in the field of COVID-19 vaccine, as well as potential barriers and recent developments in this field.

Keywords: COVID-19, Vaccines, Infection, LAV, RBD

1 Background

SARS-CoV-2, the virus that causes COVID-19, has spread around the world since December 2019. As it undergoes mutation and due to evolutionary pressures, the epidemic is spreading and becoming more dangerous, posing a greater risk. Several medicines are now being explored in clinical trials as potential repurposing candidates, however only remdesivir has been approved for the treatment of COVID-19 to date [1]. Even up with the latest approval of the antiviral drug remdesivir, as well as the Emergency Use Licensing of monoclonal antibodies against S protein, bamlanivimab and casirivimab/imdevimab, efficient and safe COVID-19 vaccines are indeed urgently needed, not only to stop the virus’s spread but also to revive social and economic activities through large scale immunization. Pfizer and BioNTech’s mRNA vaccine received Emergency Use Authorization recently, which may provide a road ahead, but long-term immunity must still be monitored, and a number of alternatives are still being developed [2]. Even though a completely effective treatment is not yet found, researches are still ongoing to find a stable therapeutic solution to impair the infection or to decrease the spreading [3]. Vaccines are of highest priority to control and eradicate the viral infectious disease COVID-19 more than any other protective solutions. Various technology
platforms are under investigation and advancement to create a competent vaccine against COVID-19 [4].

Multiple viral variants have evolved and grown prevalent in numerous nations since January 2021. The introduction of these virus variants Alpha, Beta, Gamma, and Delta was responsible for new waves of infections all across the world [5]. The advent of highly mutated (SARS-CoV-2) variant Omicron (B.1.1.529), which is a variant of concern (VOC) is now sparking fear around the world [6]. As of January 2022, WHO reports 334 vaccines are in trial of which 140 are in clinical phase and 194 in preclinical phase [7]. Vaccines in trials include protein-based or subunit and virus-like particle vaccines, virus-based or live attenuated and inactivated vaccines, and innovative gene delivery techniques such as viral vector or replicative and non-replicative and nucleic acid or DNA and RNA vaccines [8] have all been used in the development of vaccination candidates. Several big clinical trials evaluating the COVID-19 vaccines, clinical effectiveness and safety have generated promising results, despite the fact that many of these vaccines are still in pre-clinical testing. Booster doses, according to recent findings, raise neutralizing-antibody levels, which will likely act as a barrier to latest known variant’s capacity to avoid these antibodies. However, how effective these doses will be against this virus strain is unknown. People who have been exposed to the protein of the SARS-spke CoV-2 virus on multiple occasions, whether through infection or a booster dose, are more likely to have neutralising antibodies against the latest variant [9, 10].

The inability to validate and target the correct vaccination platform technologies, as well as the failure to create long-term immunity and the inability to quiet cytokine storm, are all significant roadblocks in the development of the COVID-19 vaccine. In addition to traditional vaccination forms, developing nanotechnology-based vaccine techniques are very versatile and contribute to vaccine development speed [11]. Since COVID-19 vaccine is a hot and relevant topic in this pandemic situation, we took an initiation to narrate the article. The assessment and use of currently available vaccines are in critical for a timely response to the current pandemic. We have reviewed various platforms in the field of COVID-19 vaccines although clinical trials to assess the efficiency of these vaccines are ongoing. This review describes the structure of SARS-CoV-2 and different vaccine platforms used in the development of COVID-19 in detail.

2 Main text
2.1 Structure of SARS-CoV-2
SARS-CoV-2, a beta corona virus belongs to the ‘Coronaviridae’ family with a single-stranded, positive-sense, and enclosed RNA genome ranging in size from 26.5 to 31.7 kb [12]. The spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins are the four important structural proteins encoded. The S protein promotes viral uptake into host cells by binding to the host receptor, angiotensin-converting enzyme 2 (ACE2) [13]. The S1 subunit of S protein contains the receptor binding domain or RBG which facilitates the cell attachment, the S2 component, on the other hand, is accountable for mediating the fusion of the virus’s membranes with those of the host cell [14]. Nucleocapsid (N) protein is the second structural protein that responds to the host cell and participates in the replication cycle [15]. The M protein is a three- transmembrane domain transmembrane glycoprotein. It is important in viral assembly and attaches to the nucleocapsid [16]. The final structural protein, the envelope (E) protein, which is the smallest of all structural proteins, with 76–109 amino acids and made up of hydrophobic viroporins [17]. Viroporins have a hydrophobic phospholipid coating on the outside [18]. As a result, the corona virus family’s outer membrane possesses a lipid layer, which aids in communicating with the host cell [19].

The genomic organisation of SARS-CoV-2 consists of 13–15 open reading frames (ORFs), 12 of them are functional and encode 11 protein-coding genes and 12 expressed proteins [20]. Once it enters the host cell, there occurs viral protein translation immediately with the help of a 3′-poly (A) tail and a 5′-cap. The transcriptional regulatory sequences are arranged sequentially with highly structured untranslated regions (UTRs) along a standard 5′–3′ path [21]. ORFs 1a and 1b, encode the replicate polyproteins 1a and 1ab respectively (PP1a and PP1ab). The non-structural proteins (NSPs) 1–16, that makes up the replica complex, are encased in polyprotein 1ab, which is among the biggest polyprotein. Key structural proteins S, E, M, and N are encoded at the virus genomic RNA’s 3′ end. These proteins are crucial for viral entrance, membrane fusion with the host body, and the integrity of mature viral structures [22–24]. Accessory proteins are considered to have further functions which are implicated in pathogenicity through modulation of the interferon signalling system even if not necessary for replication [25].

A set of nested subgenomic RNAs (sgRNAs) is used to translate structural and auxiliary proteins, beginning with negative-sense RNA intermediates. NSPs are also important in the pathogenesis of virus, as they play a role in transcription regulation at early stage, gene transactivation, antiviral evasion, immunomodulation, and virus replication and assembly [26–29] (Fig. 1).
2.2 Different platforms used for the development of COVID-19 vaccines

COVID-19 vaccine was developed on a variety of platforms. Available vaccine platforms are virus-based (live attenuated and inactivated), protein-based (subunit and virus-like particle) and novel gene delivery strategies such as nucleic acids (DNA and RNA) and viral vectors based (replicative and non-replicative) (Fig. 2).

2.2.1 Virus based vaccines

2.2.1.1 Live attenuated The live attenuated vaccine (LAV) requires genetic manipulation to develop low-
replication variants of the virus that cannot cause disease but can elicit a similar immune response to that seen in natural infections. It has been linked to genetic instability and the presence of residual virulence [30]. LAV has a simple production procedure that uses well-established Vero cells, which have been used for the research of vaccines for almost 40 years and were now the most widely accepted cell lineage for vaccine development by regulatory agencies. LAVs have also been shown to flourish and infect microcarrier beads without affecting production output at large-scale fermenters up to 6000 L, in serum-free conditions [31].

2.2.1.2 Inactivated To inactivate the virus, these vaccines use some chemicals such as psorlens, hydrogen peroxide ascorbic acid, ethyleneimine derivatives, β-Propiolactone, formaldehyde or physical methods like UV treatment, heat gamma irradiation etc. or the combination of the both. For inactivation of licensed human viral vaccines, formaldehyde and, β-Propiolactone are widely used in the last decades [32]. The virus can be grown in cell culture using Vero cells and inactivated using chemical methods to make SARS-CoV-2 inactivated vaccines [33, 34]. Inactivated vaccines are part of the standard viral vaccination technique. Because these vaccines contain many antigenic components, they have the ability to elicit a wide range of immune responses [35]. In compared to live-attenuated vaccinations, they are said to have less reactogenicity and are associated with lesser immune responses. For inactivated vaccines to be effective, multiple inoculations and powerful adjuvants may be required. Even while the well-established and streamlined development approach is beneficial, it does entail the handling of a live virus [36].

2.2.2 Protein-based vaccines
2.2.2.1 Subunit vaccines Purified immunogenic proteins or peptides make up subunit vaccines [37]. The majority of CoV subunit vaccines target the Spike protein, particularly its RBD which is highly immunogenic [38]. Vaccination targets include viral structural proteins such as small envelope protein E, envelope spike protein S, nucleocapsid protein N, and matrix protein M [39]. By cleaving the spike protein and permitting the S2 subunit to fuse to the cellular membrane, the serine protease, TMPRSS2 plays a role in the process [40]. SARS-CoV RBD antibodies cross-react with the respective protein, and the resultant antigena neutralises the virus, shows that a vaccination targeting the S protein domain could be successful in preventing COVID-19 [14]. The profusion-state of RBD in subunit S1 is responsible for binding to ACE2, whereas the cleavage site in subunit S2 is required for viral and cellular membrane fusion [41]. The S protein of full-length i.e., S1, S2 subunit and RBD, proteins were identified as critical epitopes for generating neutralising antibodies as per computational analyses and studies on the viruses, SARS-CoV and MERS-CoV [42, 43]. Antibodies against the RBD domain have early been shown protection against SARS and MERS-CoV infections, and the S1 epitope, containing both the RBD as well as N-terminal binding domain, NTD, has also been used to develop vaccines [44, 45]. A cluster of T cell epitope was discovered in the transmembrane part of the M protein, allowing the development of a significant cellular type of immune response against the SARS-CoV [46]. Novavax used Matrix-M adjuvant recombinant protein nanoparticle technology and the Sf9 system to develop the subunit vaccine candidate for SARS-CoV-2, the NVX-CoV2373 which comprises a trimeric full-length S-protein with the GenBank accession number MN908947 with nucleotides 21563–25384 that are missing the polybasic cleavage site, 682-QQAQ-685 was added to the S1/S2 junction to improve protease resistance, and K986P and V987P were added to enhance the stability of the recombinantly generated vaccine antigen [47] and might elicit immunological responses that were higher than those elicited by Matrix-M1 adjuvant and COVID-19 convalescent serum responses, both of which were biased toward a Th1 phenotype. The antigen in Clover Biopharmaceuticals’ S-Trimer vaccine is a recombinantly generated homotrimer of the full-length S-protein [48]. A protein subunit vaccine, also known as an adjuvanted recombinant vaccine, is assembled of virus components that enhance the human immune system without incorporating virus particles into the body [49]. Russia has recently established recombinant adenovirus vectors of type 26 (rAd26) and type 5 (rAd5), both of which carry the SARS-CoV-2 Spike protein gene. It was established that lyophilised and frozen vaccines were reported as good and safe which could induce a strong cellular and humoral immune response [50].

2.2.2.2 Virus-like particles Protein based vaccines consist of virus-like particles (VLPs), the recombinant proteins or supramolecular structures which may contain one or more copies of 10–200 nm nanoparticles assembling viral proteins [51]. Virus-like particles are created using structural proteins that have been recombinantly generated (VLPs). VLPs, the S protein of SARS-CoV-2, facilitate host cell fusion via ACE2 receptor binding and priming via TMPRSS2, unlike in subunit vaccines where VLPs seem to be unable to directly attach to B cell receptors to form the antibodies [52]. The VLPs of SARS-CoV-2, which are derived from genetically modified plants, have been shown to be effective in the production of neutralising antibodies [53].
2.2.3 Gene-based vaccines (GBVs)
GBVs encloses RNA, DNA, and the viral vector platforms and also each of them contributes peculiar advantages and disadvantages.

2.2.3.1 DNA vaccines  DNA vaccines, which are generally made up of a plasmid vector that encodes a target vaccine molecule and can elicit longer period of cellular and humoral immunity, can be mass-produced in large quantities [54]. This type of vaccine does not require the use of live viruses and may be freeze-dried and stored for a long time even though in underdeveloped countries, a major issue like power outages can be faced where some vaccine batches become inoperable [36, 55]. Through DNA vaccines, immune responses are prompted against recombinant antigens encoded by genetically engineered DNA plasmids. On post vaccination, the cellular machinery of the host enhances plasmid-encoded genes expressions which results in foreign antigens synthesis and that can be presented and processed by molecules of both class I and II MHC. The immune system is able to recognise these foreign antigens generated by the host, resulting in a complete and adequate immunization [56].

2.2.3.2 RNA vaccines  RNA-based vaccines invigorates the immunogen production via induction of both cellular and humoral immune responses. These vaccines also act on DNA based vaccine’s principle with an exception that there is no need of translocation to the nucleus for RNA transcription. They can be made from either self-replicating RNA or mRNA, mRNAs are generated with nucleoside modification to avoid the degradation, also with lipid nanoparticles like carrier molecule to allow RNA entry in to the cells [57]. BNT162b2, an mRNA vaccine candidate authorised in the United Kingdom, was the first RNA-based vaccination to be approved [58]. mRNA vaccines must be supplied to the host cell’s cytoplasm for translation into antigenic proteins and is a promising replacement for traditional protein or whole virus vaccines because of its increased efficacy for producing an immune response, safety, aloisits quick and low-cost manufacture [59]. BNT162b1, a lipid-soluble nanoparticle formulation containing mRNA encoding the S protein RBD trimer, was produced by Pfizer and BioNTech [60].

2.2.3.3 Viral vector vaccines  Viral vector vaccines consist of an often attenuated recombinant virus, designed to encode sequence of an antigen for host cell delivery for high level endogenous production of that antigen and thus induces elevated levels of cellular and humoral immune responses. These vaccines grants increased capabilities of gene transduction because of the natural host cell infection ability of the viruses [61, 62] and these are of replicating or non-replicating [4]. They are constructed to transmit one or many antigens of your choice, as well as the capacity to load a big genome suggest that a wide range of vaccines might be developed [63].

2.2.3.3.1 Non-replicating
CanSino Biological Inc. and Beijing Institute of Biotechnology’s Ad5 adenovirus vector vaccine, Ad5-nCoV, first vaccine candidate in the world to announce datas of clinical trials [64]. ChAdOx1-nCoV-19 (officially called AZD-1222) is a chimpanzee adenovirus (ChAd) recombinant vaccine produced by Oxford University and AstraZeneca that incorporates a codon optimized S protein gene added into the ChAd replication-defective mutant ChAdOx1. AZD1222 (AstraZeneca, UK) vaccination lowered SARS-CoV-2 viral load in the lungs and was protective against pneumonia, but it did not reduce viral levels in the upper respiratory tract in a challenge model of rhesus macaque. It is based on the ChAdOx1 vector, which encodes S protein and has a human tissue plasminogen activator (tPA) leader sequence flanked by poly A bovine growth hormone (BGH) signal sequence and cytomegalovirus promoter (CMV) [65]. These vaccines appeared to be safe, well tolerated, and resulted in increased levels of neutralising antibodies as well as significant ChAdOx1 nCoV-19-related side effects [66]. According to published findings from animal research, a single dose of the vaccine provided highly efficient cellular and humoral immunity. The viral load was seen much lower in vaccinated monkeys than in control monkeys after SARS-CoV-2 challenge, and pathology data revealed that in vaccinated rhesus monkeys, there was no antibody-dependent enhancement (ADE) impact and no pneumonia. A single inoculation of AZD-1222 in aged mice generated both humoral and cellular immunity however the extent was less than in young mice [67].

Gam-COVID-VacLyo (NCT04437875, renamed Sputnik V) is made up of two spike gene inserted adenoviruses, Ad5 and Ad26. The Gamaleya Research Institute in Russia developed it [68]. Sputnik V or Gam-COVID-Vac, a separate Russian vaccine candidate, contains frozen or lyophilized viral vectors of recombinant human rAd26 and rAd5 expressing the S protein. Clinical trials demonstrated that this heterologous vaccination was highly immunogenic and safe, eliciting robust cellular and humoral responses in all participants. RBD-specific IgGs were found in the majority of those who got this vaccination. Only 61% of subjects produced NAbs after receiving a single recombinant viral vector, but boosting with the additional recombinant vector boosted RBD-specific IgG titers. All of the participants produced SARS-CoV-2 NAbs after receiving the prime-boost, with titers that are
comparable to COVID-19 recovered individuals. Common and expected symptoms like discomfort at the injection site, heat, asthenia, and headache were recorded after vaccination [50]. Even 7 days after the second injection, the Sputnik V vaccine exhibited a 90 percent efficacy rate. As a result, over 50 countries requested 1.2 billion doses of the vaccine, according to the Gamaleya Institute’s second interim report [69]. Replication-defective viral vectors are widely used in non-replicating viral vaccination platforms. These are based on a weak strain of
Table 1 Various platforms of COVID-19 vaccines, types of vaccines, manufacturers and the phases it approached

| Vaccine Platforms          | Type of vaccines                          | Developers                                                                 | Phases |
|---------------------------|-------------------------------------------|---------------------------------------------------------------------------|--------|
| Inactivated viruses       | VLA2001                                   | Valneva, National Institute for Health Research, United Kingdom           | III    |
|                           | TURKOVAC,                                 | Erciyes University and the Health Institute Of Turkey (TUSEV)              | III    |
|                           | Covil-Avak                              | Shfa Pharmed Industrial Co                                                | II/III |
|                           | Vero cell, BBIBP-CorV                    | Sinopharm                                                                 | IV     |
|                           | Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018 | The Government Pharmaceutical Organization (GPO); PATH; Dynavax            | I/II   |
|                           | Inactivated COVID-19 vaccine             | KM Biologics Co., Ltd                                                    | II/III |
| Live attenuated virus     | COVI-VAC                                  | Codagenix/Serum Institute of India                                        | III    |
|                           | MV-014-212                               | Meissa Vaccines, Inc                                                     | I      |
| DNA based vaccines        | COVIGEN                                   | University of Sydney, Bionet Co., Ltd Technovalia                         | I      |
|                           | COVID-2vax                                | Takis + Rottapharm Biotech                                               | I/II   |
|                           | INO4800+-electroporation                 | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine      | III    |
|                           | AG0301-COVID19                           | AnGes + Takara Bio + Osaka University                                    | II/III |
|                           | CORVax-12                                | OncoSec Immunotherapies; Providence Health & Services                    | I      |
|                           | GX-19N                                    | Genexine Consortium                                                      | I/II   |
|                           | GLS-5310                                 | Gene One Life Science; Inc                                               | I/II   |
| Protein subunit           | VAT00008                                  | Sanofi Pasteur+ GSK                                                      | III    |
|                           | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Livzon Pharmaceutical                                                     | III    |
|                           | Recombinant SARS-CoV-2 vaccine (CHO Cell) | Institute of Microbiology, Chinese Academy of Sciences, AnhuiZhifeiLongcom Biopharmaceutical | III    |
|                           | CIGB-66 (RBD + aluminium hydroxide)     | Center for Genetic Engineering and Biotechnology (CIGB)                  | III    |
|                           | Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvant (Nanocovax) | Nanogen Pharmaceutical Biotechnology                                     | III    |
|                           | Epivac Corona                            | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector” | III    |
| RNA based vaccines        | mRNA-1273, mrRNA-1273.351                | Moderna+ National Institute of Allergy and Infectious Diseases (NAID)     | IV     |
|                           | BNT162b2 (3 LNP-mRNAs), also known as “Comirnaty” | Pfizer/BioNTech + Fosun Pharma                                          | IV     |
|                           | CYNCoVvaccine                            | CureVac AG                                                               | III    |
|                           | ARCT-021                                 | Arcturus Therapeutics                                                    | II     |
|                           | LNP-nCoVorRNA                            | Imperial College London                                                  | I      |
|                           | Chula Cov19 mRNA vaccine                  | Chulalongkorn University                                                 | I      |
|                           | SARS-CoV-2 mRNA vaccine (ARCoV)          | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | III    |
| Viral vector (non-replicating) | Recombinant novel coronavirus vaccine(Adenovirus type 5 vector) | CanSino Biological Inc./Beijing Institute of Biotechnology                | IV     |
|                           | Sputnik V (Gam-COVID-Vac) Adeno-based (rAd26-S + rAd5-S) | Gamaleya Research Institute; Health Ministry of the Russian Federation | III    |
|                           | Ad26 COV2.S                              | Janssen Pharmaceutical                                                   | IV     |
|                           | GRAd-COV2 (Replication defective Simian Adenovirus (GRAd encoding S) | ReiThera + Leukocare + Univercells                                      | I/III |
|                           | VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform | Vaxart                                                                  | II     |
|                           | MVA-SARS-2-S                             | University of Munich (Ludwig-Maximilians)                                | I      |
| Viral Vectors (Replicating)| DelNS1-2019-nCoV-RBD-OPT1 (Intranasalflu- based-RBD) | University of Hong Kong, Xiamen University and Beijing Wansui Biological Pharmacy | III   |
| Virus like particle       | rSVSARS-CoV2-2-S Vaccine                 | Israel Institute for Biological Research                                 | II/III |
|                           | Corona virus- Like Particle COVID-19 (CoVLP) | Medicago Inc                                                             | III    |
|                           | RBD SARS-CoV-2 HBsAg VLP vaccine         | Serum Institute of India + Accelagen Pty + SpyBiotech                    | I/II   |
|                           | VBI-2902a                                | VBI Vaccines Inc                                                         | I/II   |
|                           | SARS-CoV-2 VLP Vaccine                    | The Scientific and Technological Research Council of Turkey              | II     |
|                           | ABNCov2 capsid virus-like particle (CVLP) ± adjuvant MF59 | Radboud University                                                      | I      |

The data is taken from the site of WHO vaccines in clinical development [https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape](https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape)
the common cold virus, which can infect human cells but not cause illness. Adenoviruses (Ad) are one of the most common non-replicating vectors designed to simulate natural viral infection and inducing the synthesis of target viral proteins within host cells [70]. Adenovirus type 5 (Ad5) is used to make non-replicating viral vectors, and the vast majority of these vaccines use RBD subunit or S protein of SARS-CoV-2 [71].

2.2.3.3.2 Replicating
The replicating vaccines, intranasal flu vectored, DelNS1-2019-nCoV-RBD-OPT1 (Beijing Wantai Biological Pharmacy) is now in phase 3 and VSV vectored rVSV-SARS-CoV-2-S/IIBR-100 vaccine (Israel Institute for Biological Research) is in Phase 2/3 of clinical trials, and measles-vector based TMV-083 (Institut Pasteur/Themis Bioscience/Coalition for Epidemic Preparedness Innovations) is in phase 1/2 [72]. COVIVAC, Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein ± adjuvant CpG 1018, developed by Institute of Vaccines and Medical Biologicals, Vietnam is in phase1/2 and NDV-HXP-S; A Live Recombinant Newcastle Disease Virus vectored COVID-19 Vaccine, developed by Sean Liu, Icahn School of Medicine at Mount Sinai is in phase 1 [7].

Next-generation vaccines do not mandate the viral particle and can be formed merely based on the sequence of antigenic viral proteins. The material in the vaccine that provides data about the protein coding sequence generates its biosynthesis and, as a result, an immune response. Vaccines based on viral vectors, nucleic acids, or antigen-presenting cells are examples of next-generation vaccines [7, 73–75] (Fig. 3, Table 1).

3 Conclusions
The newborn outbreak of the SARS COVID-2 has been causing a serious number of mortality and morbidity in humans. Various technology platforms are under investigation and advancement to create a competent vaccine against COVID-19. The majority of COVID-19 vaccine candidates in clinical trials are primarily targeted on the viral spike protein and its variants as the primary antigen of COVID-19 infection. Subunit vaccines, inactivated vaccines, nucleic-acid-based DNA or mRNA vaccines, and viral vectored vaccinations are the most common vaccine options based on the S-antigen. It is apparent that no single vaccine winner will be there; diverse technologies and platforms can extend divergent effectiveness and relevance in discrete epidemiological contexts. Following the recent declaration of vaccine potency against COVID-19 in clinical studies by various manufacturers for protection against disease severity, an extensive post-efficacy strategy for the next steps to ensure global inoculation is already required. There are still many scientific concerns about vaccinations that need to be solved in order to improve vaccine efficacy, such as booster dosages, vaccination regime optimization, vaccine competence, correlates of protection, the function of various available diagnostic and therapeutic countermeasures against latest variant also the increased oversight. The convenient and co-ordinated administration of these post-efficacy burdens will lead the pandemic in a dynamic, and efficient, close. An effective vaccine is universally attributed in reducing the spread, severity and is crucial in preventing further morbidity and mortality. Although a few countries may deploy COVID-19 vaccines based purely on protection system and immunogenicity data, the purpose of vaccine development is to achieve solid evidence of vaccine efficacy to protect humans against COVID-19, enabling for the scale-up of efficient vaccine production.

Abbreviations
ORFs: Open reading frames; UTRs: Untranslated regions; PP1a: Polyprotein 1a; Nsp1-16: Non-structural proteins; sgRNAs: Subgenomic RNAs; Nsps: Non-structural proteins; LAV: Live attenuated vaccine; RBD: Receptor binding domain; MERS-CoV: Middle East respiratory syndrome coronavirus; TMPRSS2: Transmembrane serine protease 2; rAd26: Recombinant adenovirus type 26; VLPs: Virus-like particles; GBVs: Gene- based vaccines; tPA: Plasminogen activator; ADE: Antibody-dependent enhancement; ChAd: Chimpanzee adenovirus; CMV: Cytomegalovirus; BGH: Promoter and a bovine growth hormone.

Acknowledgements
Kannur University, Kerala, India and Council of Scientific and Industrial Research, New Delhi, India.

Authors’ contributions
SK, RS, SVK and EJV have remarkable contribution in writing and editing the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 29 November 2021 Accepted: 15 February 2022
Published online: 07 March 2022
References

1. Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifirò G (2020) Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol 11:1657.
2. Chung JY, Thone MN, Kwon YJ (2021) COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev 170:1–25.
3. Dos Santos WG (2020) Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother 129:110493.
4. Rauch S, Jasny E, Schmidt KE, Pethsch B (2018) New vaccine technologies to combat outbreak situations. Front Immunol 9:1963.
5. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Ferguson NM (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593(7858):266–269.
6. WHO. Classification of omicron (B.1.1.529). SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(B.1.1.529)-sars-cov-2-variant-of-concern-Statement. 26 November 2021.
7. https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-track-er-and-landscape
8. García-Sastre A, Mena I (2013) Novel vaccine strategies against emerging viruses. Curr Opin Virol 3(2):210–216.
9. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Ciesek S (2021) Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. MedRxiv.
10. Cele S, Jackson L, Khouy DS, Khan K, Moyo-Gwete T, Tegally H, Hanekom W (2021) SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. MedRxiv 393:142.
11. Lune N, Saville M, Hatchett R, Halton J (2020) Developing COVID-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973.
12. Woon P, Huang H, Lau SP, Yuen KY (2020) Coronavirus genomics and bioinformatics analysis. Viruses 2(8):1804–1820.
13. Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyniakidis NC, López-Cortés A (2020) Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis 98(1):115094.
14. Tai W, He L, Zhang X, Pu J, Vornon D, Jiang S, Jiang L (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17(6):613–620.
15. McBride R, van Zyl M, Fielding BC (2014) The coronavirus nucleocapsid protein is a multifunctional protein. Viruses 6(8):2991–3018.
16. Yoshimoto FK (2020) The proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or n-CoV19), the cause of COVID-19. Protein J 39:198–216.
17. Venkatagopalan P, Daskalova SM, Lopez LA, Dolezel KA, Hogue BG (2015) Coronavirus envelope (E) protein remains at the site of assembly. Virology 478:75–85.
18. Schoeman D, Fielding BC (2019) Coronavirus envelope protein: current knowledge. Virol J 16(1):1–22.
19. Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Pulcheri E, Bertelli M (2020) Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-CoV-2 infectivity? Acta Bio Med Atenei Parmensis 91(1):161.
20. Michel CJ, Mayer C, Poch O, Thompson JD (2020) Characterization of accessory genes in coronavirus genomes. Virol J 17(1):1–13.
21. Romano M, Ruggiero A, Squela F, Maga G, Beriso R (2020) A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9(5):1267.
22. Graham RL, Sparks JS, Eckerle LD, Sims AG, Denison MR (2008) SARS coronavirus replicase proteins in pathogenesis. Virus Res 133(1):88–100.
23. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Li F (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581(7807):221–224.
24. Warrick D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Mcelellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260–1263.
25. Liu DX, Fung TS, Chong KKL, Shukla A, Hilgenfeld R (2014) Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res 109:97–109.
50. Logunov DY, Dolzhikova NV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzhuraulaeva AS, Gintsburg AL (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396(10250):887–897
51. Zeiltins A (2013) Construction and characterization of virus-like particles: a review. Mol Biotechnol 53(1):92–107
52. Dai S, Wang H, Deng F (2018) Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci. https://doi.org/10.29245/2578-3009/2018/2.118
53. Prasad A, Muthamilarasan M, Prasad M (2020) Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules. Plant Cell Rep 39(9):1109–1114
54. Gurunathan S, Wu CY, Freidag BL, Seder RA (2000) DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12(4):442–447
55. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9(10):776–788
56. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB (2013) Synthetic DNA vaccines: improved vaccine potency by electroporation and codelivered genetic adjuvants. Front Immunol 4:354
57. Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Tregoning JS (2018) Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther 26(2):446–455
58. Mahase E (2020) Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. BMJ. https://doi.org/10.1136/bmj.m4714
59. Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17(4):261–279
60. Muligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Jansen KU (2020) Phase I/II study of COVID-19 mRNA vaccine BNT162b1 in adults. Nature 586(7830):589–593
61. Ura T, Okuda K, Shimada M (2014) Developments in viral vector-based vaccines. Vaccines 2(3):624–641
62. Sebastian S, Lambe T (2018) Clinical advances in viral-vectorized influenza vaccines. Vaccines 6(2):29
63. Waehler R, Russell SJ, Curie I (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8(8):573–587
64. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Chen W (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395(10240):1845–1853
65. van Doremalen N, Lambe T, Spencer A, Belay-Rammerstorfer S, Purushotham JN, Munster VJ (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586(7830):578–582
66. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586–590
67. Silva-Cayetano A, Foster W, Sinyoto, M, Belaj-Rammerstorfer S, Spencer A, J, Burton, D, Linterman, M, A, (2021) A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med, 2(3), 243–262.
68. Callaway E (2020) Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature 584(7821):334–336
69. https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficiency-for-the-sputnik-vaccine-on-d/ 
70. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S (2009) The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 7(3):226–236
71. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Chen W (2020) Immunogenicity and safety of a recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396(10249):479–488
72. Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (2021) The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics 11(4):1690
73. Soema PC, Kompier R, Amorij JP, Kersten GF (2015) Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 94:251–263
74. van Riel D, de Wit E (2020) Next-generation vaccine platforms for COVID-19. Nat Mater 19(8):810–812
75. Wallis J, Shenton DP, Carlisle RC (2019) Novel approaches for the design, delivery and administration of vaccine technologies. Clin Exp Immunol 196(2):189–204

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.